Rating Change
Guggenheim reiterated its Buy rating on MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) on October 02, 2026.
reiterateNASDAQ:MBX
Guggenheim Reiterates Buy Rating on MBX Biosciences, Inc. Common Stock (MBX)
Guggenheim reiterated its Buy rating on MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) on October 02, 2026.
At publication ·
What changed
MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) · reiterate
- Firm
- Guggenheim
- Rating
- Buy to Buy
- Price at event
- $58.29
- Market capitalization
- $954.7M
At a glance
Key takeaways
- Guggenheim reiterated a Buy rating on MBX Biosciences on October 2, 2026, with the stock trading at $58.29 and a market capitalization of $954.7 million.
Market Context
MBX Biosciences, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $58.29 with a market capitalization of $954.7M. The stock has gained 226.9% over the past 52 weeks.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for MBX Biosciences, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for MBX Biosciences, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 02, 2026 | Guggenheim | Buy | N/A |
| Aug 21, 2026 | JP Morgan | Overweight | N/A |
| Aug 10, 2026 | Truist Securities | Buy | N/A |
| Jul 29, 2026 | Mizuho | Outperform | N/A |
| May 12, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View MBX Stock Page
Frequently Asked Questions
What does the Buy rating mean for MBX?
A rating of Buy from Guggenheim reflects the analyst's outlook on MBX Biosciences, Inc. Common Stock (NASDAQ:MBX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MBX forecast page.